GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension

Status

Enrolling by invitation

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07381816

Acronym

Gastroflow

Enrollment

Registered

2026-02-02

Start date

2025-09-15

Completion date

2027-05-01

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Flow, Healthy, Postprandial Hypotension

Keywords

Physiology, GIP, Blood flow, Postprandial hypotension, Splanchnic blood flow, Mesenteric blood flow

Brief summary

This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with postprandial hypotension.

Detailed description

Each participant will attend three independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). Furthermore one day will be with handgrip exercise, without an infusion. Therefore the first two days are in randomized order. MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines and pancreas.

Interventions

OTHERMRI + GIPR antagonist (Tool)

GIP(3-30)NH2 infusion, oral glucose during MRI scans

OTHERMRI + hangrip

Hangrip exercises, oral glucose during MRI scans

OTHERSaline and oral glucose

Saline infusion oral glucose during MRI scans

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Intervention model description

Single blind, placebo controlled, randomized, crossover study

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

For the PPH group Inclusion Criteria: * Postprandial hypotension * Symptoms of postprandial hypotension

Exclusion criteria

* Treatment with drugs that cannot be paused for 12 hours * Metallic implants that does not tolerate MRI * Any other disease or dysfunction that may disturb blood flow to the gut * Intake of more than 14 units of alcohol per week or abuse of drugs * Blood vessels that are not feasible for measuring flow in the MRI scanner * Low blood percent * Decreased kidney function * Decreased liver function * Claustrophobia For the healthy group Inclusion Criteria: * Matched by age, gender and BMI

Design outcomes

Primary

Measure	Time frame	Description
Blood flow	145 minutes	Redistribution of splanchnic blood flow in the vessel mesenteric superior artery. Measured with functional MRI in ml/min

Secondary

Measure	Time frame	Description
Blood flow	145 minutes	Blood flow in vena portae

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026